作者：奥利克·米拉契奇，马里亚，2015-10-14
评论:Zaccara, Sara, 2016-02-04
审查：Inga，Alberto，2016-02-04
编辑:Orlic-Milacic, Marija, 2015-10-14
TP53结合PRDM1基因
TP53结合PRDM1基因
TP53 (p53)结合PRDM1 (BLIMP1)基因第三内含子中的p53应答元件(Yan et al. 2007)。
作者：奥利克·米拉契奇，马里亚，2015-10-14
评论:Zaccara, Sara, 2016-02-04
审查：Inga，Alberto，2016-02-04
编辑:Orlic-Milacic, Marija, 2015-10-14
反应数据库ID:6804192
1
骨髓
走
0005654.
ENSEMBL：ENSG00000057657 PRDM1
PRDM1
Blimp1.
反应
//www.joaskin.com
智人
NCBI分类法
9606.
ENSEMBL
ENSG00000057657.
反应DB_ID：3222171
1
P-S15，S20-TP53四聚体[核质]
P-S15，S20-TP53四聚体
反应DB_ID：69683
4
UniProt:P04637 TP53
TP53
TP53
P53.
功能用作许多肿瘤类型中的肿瘤抑制剂;根据生理环境和细胞类型诱导生长停滞或细胞凋亡。参与细胞周期调节作为跨活化剂，其通过控制该方法所需的一组基因来作用于负调节细胞分裂。其中一种活化基因是细胞周期蛋白依赖性激酶的抑制剂。凋亡诱导似乎通过刺激BAX和Fas抗原表达或通过抑制Bcl-2表达来介导。其促凋亡活性通过其与PPP1R13B / ASPP1或TP53BP2 / ASPP2的相互作用而激活（PubMed：12524540）。然而，当与PPP1R13B / ASPP1或TP53BP2 / ASPP2的相互作用通过PPP1R13L / IASPP移位时，该活性受到抑制（PPP1R13L / IASPP（PUBMED：12524540）。与线粒体PPIF合作，参与激活氧化应激诱发的坏死;该功能在很大程度上与转录无关。诱导长期非编码RNA P21（LincrNA-P21）和LincrNA-MKLN1的转录。 LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492).SUBUNIT Forms homodimers and homotetramers (PubMed:19011621). Binds DNA as a homotetramer. Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity (By similarity). Interacts with ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. Interacts with YWHAZ; the interaction enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). Interacts with MDM2; leading to ubiquitination and proteasomal degradation of TP53. Directly interacts with FBXO42; leading to ubiquitination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation. Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the association implicates preferentially tetrameric TP53, is induced by oxidative stress and is impaired by cyclosporin A (CsA). Interacts with SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with KAT6A. Interacts with UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via DNA-binding domain) with ZNF385A; the interaction is direct and enhances p53/TP53 transactivation functions on cell-cycle arrest target genes, resulting in growth arrest. Interacts with ANKRD2. Interacts with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via oligomerization region) with NOP53; the interaction is direct and may prevent the MDM2-mediated proteasomal degradation of TP53 (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial translocation of TP53 (PubMed:27323408). Interacts with UBD (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 (PubMed:20096117). Interacts with C10orf90/FATS; the interaction inhibits binding of TP53 and MDM2 (By similarity). Interacts with NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a complex with EP300 and NUPR1; this complex binds CDKN1A promoter leading to transcriptional induction of CDKN1A (PubMed:18690848). Interacts with PRMT5 in response to DNA damage; the interaction is STRAP dependent (PubMed:19011621). Interacts with PPP1R13L (via SH3 domain and ANK repeats); the interaction inhibits pro-apoptotic activity of p53/TP53 (PubMed:12524540). Interacts with PPP1R13B/ASPP1 and TP53BP2/ASPP2; the interactions promotes pro-apoptotic activity (PubMed:12524540). When phosphorylated at Ser-15, interacts with DDX3X and gamma-tubulin (PubMed:28842590). Interacts with KAT7/HBO1; leading to inhibit histone acetyltransferase activity of KAT7/HBO1 (PubMed:17954561). Interacts (via N-terminus) with E3 ubiquitin-protein ligase MUL1; the interaction results in ubiquitination of cytoplasmic TP53 at Lys-24 and subsequent proteasomal degradation (PubMed:21597459). Interacts with S100A4; this interaction promotes TP53 degradation (PubMed:23752197, PubMed:32442400).SUBUNIT (Microbial infection) Interacts with cancer-associated/HPV E6 viral proteins leading to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6.SUBUNIT (Microbial infection) Interacts with human cytomegalovirus/HHV-5 protein UL123.SUBUNIT (Microbial infection) Interacts (via N-terminus) with human adenovirus 5 E1B-55K protein; this interaction leads to the inhibition of TP53 function and/or its degradation.TISSUE SPECIFICITY Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.INDUCTION Up-regulated in response to DNA damage. Isoform 2 is not induced in tumor cells in response to stress.DOMAIN The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.PTM Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence. Deacetylation by SIRT2 impairs its ability to induce transcription activation in a AKT-dependent manner.PTM Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to be mediated by STK11/LKB1 but it was later shown that it is indirect and that STK11/LKB1-dependent phosphorylation is probably mediated by downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 results in a reduction in ubiquitination by MDM2 and an increase in acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53, particularly in the nucleus, thus inducing the transactivation of p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA-damage. Phosphorylation at Ser-15 is required for interaction with DDX3X and gamma-tubulin (PubMed:28842590).PTM Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.PTM May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.PTM Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, PubMed:17170702, PubMed:19880522). Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome (PubMed:10722742, PubMed:12810724, PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation (PubMed:19556538). Ubiquitination by TOPORS induces degradation (PubMed:19473992). Deubiquitination by USP7, leading to stabilization (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2-independent manner (PubMed:15340061). Ubiquitinated by COP1, which leads to proteasomal degradation (PubMed:19837670). Ubiquitination and subsequent proteasomal degradation is negatively regulated by CCAR2 (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, leading to TP53 stabilization (By similarity). Polyubiquitinated by MUL1 at Lys-24 which leads to proteasomal degradation (PubMed:21597459).PTM Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation (PubMed:15525938, PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity (PubMed:17108971). Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370 (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting interaction with L3MBTL1 and leading to repress transcriptional activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 diminishes p53 ubiquitination, through stabilizing association with the methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation (PubMed:17805299). Monomethylated at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; methylation is increased after DNA damage and might possibly affect TP53 target gene specificity (PubMed:19011621).PTM Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9.DISEASE TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.SIMILARITY Belongs to the p53 family.
UniProt
P04637
O-phospho-L-serine在20
20.
平等的
O-磷酸-L-丝氨酸[MOD：00046]
O-phospho-L-serine 15岁
15
平等的
链坐标
1
平等的
393
平等的
反应数据库ID版本77
3222171
数据库标识符。使用此URL连接到Reactome中此实例的网页：//www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=3222171
反应
r - hsa - 3222171
1
反应稳定标识符。使用此URL连接到Reactome中此实例的网页：//www.joaskin.com/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-3222171.1
反应数据库ID:6804190
1
p-S15 S20-TP53: PRDM1基因(核浆)
P-S15，S20-TP53：PRDM1基因
反应数据库ID:6804192
1
反应DB_ID：3222171
1
反应数据库ID版本77
6804190
数据库标识符。使用此URL连接到Reactome中的此实例的网页://www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=6804190
反应
R-HSA-6804190
1
Reactome稳定的标识符。使用此URL在反弹中连接到此实例的网页：http：//www.reacontome.org/cgi-bin/eventbrowser_st_id?st_id=r-hsa -6804190.1
反应数据库ID版本77
6804191.
数据库标识符。使用此URL连接到Reactome中的此实例的网页://www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=6804191
反应
R-HSA-6804191
2
Reactome稳定的标识符。使用此URL连接到Reactome中的此实例的网页://www.joaskin.com/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-6804191.2
17264218
PubMed.
2007年
Blimp1通过抑制P53转录来调节细胞生长
颜俊丽
江,Jianming
Lim Ching Aeng
吴,羌族
NG，Huck-Hui
下巴，keh-chuang
Proc。国家的。学会科学。美国104:1841-6
TP53刺激PRDM1表达
TP53刺激PRDM1表达
TP53（P53）与PRDM1（Blimp1）基因的第三内含子中的P53响应元件的结合刺激Blimp1转录（Yan等人2007）。
作者：奥利克·米拉契奇，马里亚，2015-10-14
评论:Zaccara, Sara, 2016-02-04
审查：Inga，Alberto，2016-02-04
编辑:Orlic-Milacic, Marija, 2015-10-14
反应数据库ID:6804192
1
Reactome DB_ID: 6804199
1
UniProt: O75626 PRDM1
PRDM1
PRDM1
Blimp1.
功能转录因子，在各种先天性和适应性免疫组织驻留淋巴细胞T细胞类型中介导转录程序，如组织驻留记忆T（Trm）、自然杀伤T（trNK）和自然杀伤T（NKT）细胞和负性调节蛋白质的基因表达，这些蛋白质促进组织驻留的T细胞群从非淋巴器官中排出。在非淋巴样器官（如皮肤和肠道）以及其他非屏障组织（如肝脏和肾脏）的适应性和先天性组织驻留淋巴细胞T细胞类型的发育、保留和长期建立中发挥作用，因此可以提供即时免疫保护，防止再次激活的感染或病毒再感染（通过相似性）。特异性结合β干扰素基因启动子中的PRDI元件（PubMed:1851123）。促使B淋巴细胞成熟为Ig分泌细胞（PubMed:12626569）。与转录阻遏子ZNF683在基因启动子区域与染色质结合（通过相似性）。亚单位与PRMT5相互作用（通过相似性）。与FBXO10交互（PubMed:24613396）。与FBXO11交互（PubMed:24613396，PubMed:24968003）。与多种核苏甲酰化E3连接酶相互作用，包括CBX4、PIAS1、PIAS2、PIAS3、PIAS4、PML和RNF4，但不与RANBP2相互作用（PubMed:2884258）。与LDB1、SMARCD3和SMARCC1相互作用（PubMed:32417234）。通过PIAS1在Lys-816的PTM磺酰化可增强转录阻遏物活性，并对浆细胞分化至关重要（PubMed:225555612）。可通过PML与SUMO1和SUMO2进行SUMO化。野生型蛋白质的降解主要取决于苏木酰化，而不是泛素化（PubMed:2884258）。通过SENP1和SENP6（PubMed:2884258）去磺酰化。PTM被SCF（FBXO11）复合物泛素化，导致其被蛋白酶体降解。在某些活化B细胞样弥漫性大B细胞淋巴瘤（ABC-DLBCL）的侵袭性病例中，已观察到PRDM1蛋白不稳定性。这种损害B细胞分化的不稳定性是由N端错误折叠突变引起的，包括发生在Pro-84和Ile-107位置的突变，并导致PRDM1蛋白在细胞质中隔离，随后通过热休克蛋白70 HSPA1A-SYNV1/HRD1途径进行蛋白酶体降解。这些N末端突变不影响PRDM1转录调节活性。HSPA1A抑制比蛋白酶体抑制更有效地恢复淋巴瘤细胞系中PRDM1的核定位和转录活性，并抑制异种移植物中的肿瘤生长。相似性属于V类SAM结合甲基转移酶超家族。
UniProt
O75626
1
平等的
825
平等的
反应数据库ID版本77
6804193.
数据库标识符。使用此URL连接到Reactome中的此实例的网页://www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=6804193
反应
R-HSA-6804193
3.
Reactome稳定的标识符。使用此URL在反弹中连接到此实例的网页：http：//www.reacectome.org/cgi-bin/eventbrowser_st_id?st_id=r-hsa -6804193.3
激活
反应数据库ID版本77
6804186
数据库标识符。使用此URL连接到Reactome中此实例的网页：//www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=6804186
反应
R-HSA-6804186
1
Reactome稳定的标识符。使用此URL在反弹中连接到此实例的网页：http：//www.reacontome.org/cgi-bin/eventbrowser_st_id?st_id=r-hsa -6804186.1
反应数据库ID:6804190
PRDM1结合TP53基因
PRDM1结合TP53基因
PRDM1（Blimp1）锌指转录因子在TP53（P53）基因的转录开始部位附近（Yan等人2007）。
作者：奥利克·米拉契奇，马里亚，2015-10-14
评论:Zaccara, Sara, 2016-02-04
审查：Inga，Alberto，2016-02-04
编辑:Orlic-Milacic, Marija, 2015-10-14
反应数据库ID:6797244
1
Ensembl：ENSG00000141510 TP53
TP53
P53.
ENSEMBL
ENSG00000141510
Reactome DB_ID: 6804199
1
1
平等的
825
平等的
反应DB_ID：6804203
1
PRDM1:TP53基因[核质]
PRDM1: TP53基因
反应数据库ID:6797244
1
Reactome DB_ID: 6804199
1
1
平等的
825
平等的
反应数据库ID版本77
6804203
数据库标识符。使用此URL连接到Reactome中的此实例的网页://www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=6804203
反应
R-HSA-6804203
1
反应稳定标识符。使用此URL连接到Reactome中此实例的网页：//www.joaskin.com/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-6804203.1
反应数据库ID版本77
6804194
数据库标识符。使用此URL连接到Reactome中的此实例的网页://www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=6804194
反应
R-HSA-6804194
1
Reactome稳定的标识符。使用此URL将此实例的Web页面连接到Reactome：http：//www.reacontome.org/cgi-bin/eventbrowser_st_id?st_id=r-hsa-6804194.1
PRDM1抑制TP53表达
PRDM1抑制TP53表达
PRDM1 (BLIMP1)与TP53 (p53)基因启动子区域的结合可能通过诱导TP53启动子的抑制性甲基化抑制TP53的转录(Yan et al. 2007) (Weige et al. 2014)。
作者：奥利克·米拉契奇，马里亚，2015-10-14
评论:Zaccara, Sara, 2016-02-04
审查：Inga，Alberto，2016-02-04
编辑:Orlic-Milacic, Marija, 2015-10-14
反应数据库ID:6797244
1
Reactome DB_ID: 69488
1
1
平等的
393
平等的
反应数据库ID版本77
6804188
数据库标识符。使用此URL连接到Reactome中此实例的网页：//www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=6804188
反应
R-HSA-6804188
3.
Reactome稳定的标识符。使用此URL连接到Reactome中的此实例的网页://www.joaskin.com/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-6804188.3
24743655
PubMed.
2014年
非裔美国人早发结肠癌TP53等位基因特异性模型中的转录组和shRNA抑制物
威格，查尔斯C.
Birtwistle，Marc R
马立克，希梅尔
易，宁君
贝荣，祖扎纳
克洛斯纳，艾米莉
达夫，基利
Tidwell,约瑟芬
克莱登宁，梅根
Wilkerson，Brent.
法拉雷，克里斯托弗
Bunz，Fred.
吉，郝
Shtutman,迈克尔
溪,金E
卡萝琳·E·巴尼斯特酒店
Buckhaults,菲利普J
Mol. Cancer res: 12:1029-41
抑制
反应数据库ID版本77
6804227
数据库标识符。使用此URL连接到Reactome中此实例的网页：//www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=6804227
反应
R-HSA-6804227
1
反应稳定标识符。使用此URL连接到Reactome中此实例的网页：//www.joaskin.com/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-6804227.1
反应DB_ID：6804203
TP53形式homotetramers
TP53形式homotetramers
TP53（P53）用作稳定的同性恋。四聚化结构域位于C-Terminus（Stenger等人1994，Waterman等，1995，Jeffrey等，1995，Wang等人。1995）。
作者：奥利克·米拉契奇，马里亚，2015-10-14
评论:Zaccara, Sara, 2016-02-04
审查：Inga，Alberto，2016-02-04
综述：萨卡鲁奇，Kazuyasu，2021-04-30
编辑:Orlic-Milacic, Marija, 2015-10-14
Reactome DB_ID: 69488
4
1
平等的
393
平等的
反应DB_ID：3209194
1
TP53四聚物(核浆)
TP53四聚物
Reactome DB_ID: 69488
4
1
平等的
393
平等的
反应数据库ID版本77
3209194
数据库标识符。使用此URL连接到Reactome中此实例的网页：//www.joaskin.com/cgi-bin/eventbrowser?DB=gk_current&ID=3209194
反应
r - hsa - 3209194
1
反应稳定标识符。使用此URL连接到Reactome中此实例的网页：//www.joaskin.com/cgi-bin/eventbrowser_st_id?ST_ID=R-HSA-3209194.1
反应数据库ID版本77
6804762
数据库标识符。使用此URL在反弹中连接到此实例的网页：http：//www.reacontome.org/cgi-bin/eventbrowser?db=gk_current&id=6804762
反应
R-HSA-6804762
2
Reactome稳定的标识符。使用此URL将此实例的Web页面连接到Reactome：http：//www.reacontome.org/cgi-bin/eventbrowser_st_id?st_id=r-hsa -6804762.2
7813439
PubMed.
1994
p53寡聚化和DNA环化与转录激活有关
轮J E
特格梅耶，P
梅尔，G a
里德,M
王，Y
王，P
霍夫，p v
Mastrangelo，我
EMBO j . 13:6011-20
7859740
PubMed.
1995
P53四聚化结构域的二对称对称性要求DNA结合时构象开关
Waterman，J L.
Shenk，J L.
Halazonetis T D
EMBO j . 14:512-9
7891710
PubMed.
1995
p53与其一致的dna结合位点的相互作用
王，Y
Schwedes J F
公园、维
曼恩，K
特格梅耶，P
摩尔。细胞。BIOL。15：2157-65
7878469
PubMed.
1995
P53肿瘤抑制器的四聚化结构域的晶体结构在1.7埃
杰弗里，PD.
戈里娜，S
帕夫莱蒂奇，NP
科学267:1498-502
反应数据库ID版本77
6804754
数据库标识符。使用此URL将此实例的网页连接到反乐中：http：//www.reacontome.org/cgi-bin/eventbrowser?db=gk_current&id=6804754
反应
R-HSA-6804754
1
Reactome稳定的标识符。使用此URL将此实例的网页连接到反乐中：http：//www.reacectome.org/cgi-bin/eventbrowser_st_id?st_id=r-hsa -6804754.1
